en
Scientific article
Review
Open access
English

Prophylaxis for COVID-19: a systematic review

Published inClinical microbiology and infection, vol. 27, no. 4, p. 532-537
Publication date2021-04
First online date2021-01-18
Abstract

Background: While the landscape of vaccine and treatment candidates against the novel coronavirus disease 2019 (COVID-19) has been reviewed systematically, prophylactic candidates remain unexplored.

Objectives: To map pre- and postexposure prophylactic (PrEP and PEP) candidate for COVID-19.

Data sources: PubMed/Medline, Embase, International Committee of Medical Journal Editors and International Clinical Trials Registry Platform clinical trial registries and medRxiv.

Study eligibility criteria and participants: All studies in humans or animals and randomized controlled trials (RCTs) in humans reporting primary data on prophylactic candidates against COVID-19, excluding studies focused on key populations.

Interventions: PrEP and PEP candidate for COVID-19.

Methods: Systematic review and qualitative synthesis of COVID-19 PrEP and PEP studies and RCTs complemented by search of medRxiv and PubMed and Embase for studies reporting RCT outcomes since systematic review search completion.

Results: We identified 13 studies (from 2119 database records) and 117 RCTs (from 5565 RCTs listed in the registries) that met the inclusion criteria. Non-RCT studies reported on cross-sectional studies using hydroxychloroquine (HCQ) in humans (n = 2) or reported on animal studies (n = 7), most of which used antibodies. All five completed RCTs focused on the use of HCQ as either PrEP or PEP, and these and the cross-sectional studies reported no prophylactic effect. The majority of ongoing RCTs evaluated HCQ or other existing candidates including non-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines, anti(retro)virals or use of vitamins and supplements.

Conclusions: The key message from completed studies and RCTs seems to be that HCQ does not work. There is little evidence regarding other compounds, with all RCTs using candidates other than HCQ still ongoing. It remains to be seen if the portfolio of existing molecules being evaluated in RCTs will identify successful prophylaxis against COVID-19 or if there is a need for the development of new candidates.

eng
Keywords
  • COVID-19
  • Prophylaxis
  • Randomized control trials
  • SARS-CoV-2
  • Systematic review
  • Animals
  • Antibodies, Monoclonal / therapeutic use
  • Antibodies, Neutralizing / therapeutic use
  • Antibodies, Viral / therapeutic use
  • Antimalarials / therapeutic use
  • Antiviral Agents / therapeutic use
  • COVID-19 / prevention & control
  • Humans
  • Hydroxychloroquine / therapeutic use
  • Post-Exposure Prophylaxis
  • Pre-Exposure Prophylaxis
  • Randomized Controlled Trials as Topic
  • SARS-CoV-2 / immunology
  • Vaccines
Research group
Citation (ISO format)
SMIT, Mikaëla et al. Prophylaxis for COVID-19: a systematic review. In: Clinical microbiology and infection, 2021, vol. 27, n° 4, p. 532–537. doi: 10.1016/j.cmi.2021.01.013
Main files (1)
Article (Published version)
Secondary files (1)
Identifiers
ISSN of the journal1198-743X
15views
13downloads

Technical informations

Creation02/23/2022 2:40:13 PM
First validation11/17/2023 5:46:02 PM
Update time11/17/2023 5:46:02 PM
Status update11/17/2023 5:46:02 PM
Last indexation05/06/2024 5:24:05 PM
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack